Skip to main content

Advertisement

SpringerLink
Log in

Pepinemab (Anti-SEMA4D) in Combination with Ipilimumab or Nivolumab for Patients with Resectable Pancreatic and Colorectal Cancer

  • ASO Research Letter
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Mastrantonio R, You H, Tamagnone L. Semaphorins as emerging clinical biomarkers and therapeutic targets in cancer. Theranostics. 2021;11:3262–77.

    Article  CAS  Google Scholar 

  2. Wang JS, Jing CQ, Shan KS, et al. Semaphorin 4D and hypoxia-inducible factor-1α overexpression is related to prognosis in colorectal carcinoma. World J Gastroenterol. 2015;21:2191–8.

    Article  CAS  Google Scholar 

  3. Ding X, Qiu L, Zhang L, et al. The role of semaphorin 4D as a potential biomarker for antiangiogenic therapy in colorectal cancer. OncoTargets Ther. 2016;9:1189–204.

    CAS  Google Scholar 

  4. Tamagnone L, Franzolin G. Targeting semaphorin 4D in cancer: a look from different perspectives. Cancer Res. 2019;79:5146–8.

    Article  CAS  Google Scholar 

  5. Patnaik A, Ramanathan RK, Rasco DW, et al. Phase 1 study of VX15/2503, a humanized IgG4 anti-SEMA4D antibody, in advanced cancer patients (pts). J Clin Oncol. 2014;32(15 Suppl):3052.

Download references

Author information

Authors and Affiliations

  1. Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

    Alexander J. Rossi MD, Tahsin M. Khan MD, Hanna Hong BS & Jonathan M. Hernandez MD

  2. Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA, USA

    Gregory B. Lesinski Phd, MPH & Christina Wu MD

Authors
  1. Alexander J. Rossi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tahsin M. Khan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hanna Hong BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gregory B. Lesinski Phd, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Christina Wu MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jonathan M. Hernandez MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Christina Wu MD or Jonathan M. Hernandez MD.

Ethics declarations

Disclosure

Gregory Lesinski received funding via sponsored research agreements through Emory University for research from Vaccinex. The remaining authors have no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 145 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rossi, A.J., Khan, T.M., Hong, H. et al. Pepinemab (Anti-SEMA4D) in Combination with Ipilimumab or Nivolumab for Patients with Resectable Pancreatic and Colorectal Cancer. Ann Surg Oncol 28, 4098–4099 (2021). https://doi.org/10.1245/s10434-021-10111-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-021-10111-0

Search

Navigation